Table 1.
Demographic and treatment data of study population.
| Control (n = 17) | RSV (n = 23) | |
|---|---|---|
| Male/Female | 9/8 | 14/9 |
| Agea (range) | 1.7 (0.1 - 8.7) | 3.3 (0.4 - 10.1) |
| Gestational agea (range) | 37.3 (30 - 39) | 36.8 (28 - 39) |
| Family history of asthma | 13.3% | 21.7% |
| Household smokers | 13.3% | 21.7% |
| Prev. respiratory infection | 6.7% | 13% |
| Siblings | 66.6% | 85.7% |
| Household pets | 37.5% | 13% |
| Palivizumab | 6.3% | 8.7% |
| Oxygen received | NA | 21 (91%) |
| Use of CPAP | NA | 8 (35%) |
| Use of heliox | NA | 0 (0%) |
| Mechanical ventilation | NA | 5 (22%) |
| Steroids | NA | 3 (13%) |
| Albuterol | NA | 8 (35%) |
a
Average in months